(Q36133796)

12 August 2017

1 reference

title

First-episode schizophrenia: a focus on pharmacological treatment and safety considerations (English)

1 reference

12 August 2017

1 reference

2

Robert R Conley

1 reference

12 August 2017

Deanna L Kelly

1

1 reference

12 August 2017

William T Carpenter

series ordinal

3

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

65

1 reference

12 August 2017

issue

8

1 reference

12 August 2017

page(s)

1113-1138

1 reference

Schizophrenics kill themselves too: a review of risk factors for suicide

12 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200565080-00006

Olanzapine increases weight and serum triglyceride levels.

21 January 2018

1 reference

12 December 2020

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

1 reference

12 December 2020

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

1 reference

12 December 2020

New antipsychotics and schizophrenia: a review on efficacy and side effects

1 reference

12 December 2020

Gynecomastia with risperidone-fluoxetine combination

1 reference

12 December 2020

Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone

1 reference

12 December 2020

Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone

1 reference

12 December 2020

From compliance to collaboration in the treatment of schizophrenia.

1 reference

12 December 2020

Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability

1 reference

12 December 2020

Drugs, QT interval abnormalities and ventricular arrhythmias.

1 reference

12 December 2020

Antiarrhythmic drugs and torsade de pointes

1 reference

12 December 2020

Course of treatment response in first-episode and chronic schizophrenia

1 reference

12 December 2020

The role of prolactin in mammary carcinoma

1 reference

12 December 2020

The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia

1 reference

12 December 2020

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

12 December 2020

Hyperglycemia and antipsychotic medications.

1 reference

12 December 2020

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

1 reference

12 December 2020

Neuropsychological differences between first-admission schizophrenia and psychotic affective disorders.

1 reference

12 December 2020

The evaluation and treatment of first-episode psychosis

1 reference

12 December 2020

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

12 December 2020

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

1 reference

12 December 2020

Psychiatric and social reasons for frequent rehospitalization

1 reference

12 December 2020

Risperidone-associated galactorrhea in a male teenager

1 reference

12 December 2020

Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study

1 reference

12 December 2020

Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy

1 reference

12 December 2020

Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.

1 reference

12 December 2020

Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission

1 reference

12 December 2020

Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study

1 reference

12 December 2020

Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations

1 reference

12 December 2020

Priapism from quetiapine overdose: first report and proposal of mechanism

1 reference

12 December 2020

Endocrine effects of psychotropic drugs: VI. Male sexual function

1 reference

12 December 2020

Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.

1 reference

12 December 2020

Dosing the antipsychotic medication olanzapine

1 reference

12 December 2020

Developmental abnormalities of the hippocampus in first-episode schizophrenia.

1 reference

12 December 2020

The nature and prevalence of depression in chronic schizophrenic in-patients

1 reference

12 December 2020

Clozapine for first-episode schizophrenia

1 reference

12 December 2020

Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies

1 reference

12 December 2020

Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness

1 reference

12 December 2020

Risperidone-associated new-onset diabetes

1 reference

12 December 2020

Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis

1 reference

12 December 2020

Prolactin as an autocrine/paracrine factor in breast tissue

1 reference

12 December 2020

Olanzapine-induced elevation of plasma triglyceride levels

1 reference

12 December 2020

Prolactin levels and adverse events in patients treated with risperidone.

1 reference

12 December 2020

Metabolic consequences of atypical antipsychotic drugs

1 reference

12 December 2020

Depression in people with first-episode schizophrenia

1 reference

12 December 2020

Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders

1 reference

12 December 2020

Violent patients in the emergency setting

1 reference

12 December 2020

Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.

1 reference

12 December 2020

Dopamine agonists in schizophrenia: a review

1 reference

12 December 2020

Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight

1 reference

12 December 2020

Management of antidepressant-induced side effects: a practical guide for the clinician.

1 reference

12 December 2020

Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects

1 reference

12 December 2020

The rationale and ethics of medication-free research in schizophrenia

1 reference

12 December 2020

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

1 reference

12 December 2020

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

1 reference

12 December 2020

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

1 reference

12 December 2020

The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.

1 reference

12 December 2020

1 reference

12 December 2020

Elevation of prolactin levels by atypical antipsychotics

1 reference

12 December 2020

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

12 December 2020

Depression in chronic schizophrenia

1 reference

12 December 2020

Patient choice: deciding between psychotropic medication and physical restraints in an emergency

1 reference

12 December 2020

Genitourinary and sexual adverse effects of psychotropic medication

1 reference

12 December 2020

Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.

1 reference

12 December 2020

Predictors of noncompliance in patients with schizophrenia.

1 reference

12 December 2020

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

1 reference

12 December 2020

The effect of acute hyperglycaemia on QTc duration in healthy man

1 reference

12 December 2020

Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning.

1 reference

12 December 2020

The occurrence of organic disease of possible or probable aetiological significance in a population of 268 cases of first episode schizophrenia.

1 reference

12 December 2020

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

12 December 2020

Substance misuse at presentation to an early psychosis program

1 reference

12 December 2020

Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk

1 reference

12 December 2020

Conditions predisposing to suicide: a review

1 reference

12 December 2020

Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.

1 reference

12 December 2020

First-episode studies in schizophrenia: criteria and characterization

1 reference

12 December 2020

Clinical effectiveness of oral and parenteral rapid neuroleptization

1 reference

12 December 2020

Medication adherence of individuals with a first episode of psychosis

1 reference

12 December 2020

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study

1 reference

12 December 2020

Are dopamine antagonists a risk factor for breast cancer? An answer from Parkinson's disease

1 reference

12 December 2020

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

12 December 2020

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology

1 reference

12 December 2020

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

1 reference

12 December 2020

Early detection and intervention for initial episodes of schizophrenia

1 reference

12 December 2020

Acute quetiapine poisoning

1 reference

12 December 2020

Antidepressant Usage in Schizophrenia

1 reference

12 December 2020

Symptom Outcome 1 Year after Admission to an Early Psychosis Program

1 reference

12 December 2020

Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study

1 reference

12 December 2020

Risperidone and associated amenorrhea: a report of 5 cases.

1 reference

12 December 2020

Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences

1 reference

12 December 2020

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Elevated prolactin in pediatric patients on typical and atypical antipsychotics.

1 reference

12 December 2020

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

12 December 2020

A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic

1 reference

12 December 2020

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

1 reference

12 December 2020

Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?

1 reference

12 December 2020

Aripiprazole: a review of its pharmacology and clinical use.

1 reference

12 December 2020

Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months

1 reference

12 December 2020

Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study

1 reference

12 December 2020

Risperidone-associated priapism

1 reference

12 December 2020

Olanzapine-induced glucose dysregulation.

1 reference

12 December 2020

Prolactogenic effects of risperidone in male patients--a preliminary study

1 reference

12 December 2020

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

1 reference

12 December 2020

Risk factors for suicide in patients with schizophrenia: nested case-control study.

1 reference

12 December 2020

QTc prolongation and high-dose olanzapine.

1 reference

12 December 2020

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications

1 reference

12 December 2020

A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group

1 reference

12 December 2020

Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety

1 reference

12 December 2020

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

12 December 2020

Risperidone-induced absence of ejaculation

1 reference

12 December 2020

Integrating incidence and prevalence of tardive dyskinesia

1 reference

12 December 2020

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

12 December 2020

Movement disorders associated with atypical antipsychotic drugs

1 reference

12 December 2020

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

1 reference

12 December 2020

Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study

1 reference

12 December 2020

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

12 December 2020

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

12 December 2020

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

1 reference

12 December 2020

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

12 December 2020

Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases

1 reference

12 December 2020

The long-term effects of placebo in patients with chronic schizophrenia.

1 reference

12 December 2020

A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia

1 reference

12 December 2020

Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia

1 reference

12 December 2020

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Determinants of medication compliance in schizophrenia: empirical and clinical findings

1 reference

12 December 2020

Olanzapine-induced ketoacidosis with diabetes mellitus

1 reference

12 December 2020

Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.

1 reference

12 December 2020

Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients

1 reference

12 December 2020

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

12 December 2020

Olanzapine-associated diabetes mellitus

1 reference

12 December 2020

Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients

1 reference

12 December 2020

Cardiovascular consequences of the obesity pandemic: need for action

1 reference

12 December 2020

Risperidone-induced priapism

1 reference

12 December 2020

Predictors of acute dystonia in first-episode psychotic patients.

1 reference

12 December 2020

Adherence in chronic disease

1 reference

12 December 2020

Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study

1 reference

12 December 2020

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

12 December 2020

Impaired sexual intercourse as a complication of tardive dyskinesia

1 reference

12 December 2020

Emergency psychiatry: extrapyramidal side effects in the psychiatric emergency service

1 reference

12 December 2020

Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients

1 reference

12 December 2020

Atypical antipsychotic drugs and long-term outcome in schizophrenia

1 reference

12 December 2020

Antipsychotic agents and QT changes.

1 reference

12 December 2020

Epidemiology, morbidity, and treatment of overweight and obesity.

1 reference

12 December 2020

Focal neuroleptization: an approach to optimal dosing for initial and continuing therapy.

1 reference

12 December 2020

Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin

1 reference

12 December 2020

Compliance with antipsychotic drug treatment: influence of side effects.

1 reference

12 December 2020

Compliance in adolescents with chronic diseases: a review.

1 reference

12 December 2020

Auditing first episode psychosis: giving meaning to clinical governance

1 reference

12 December 2020

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital

1 reference

12 December 2020

Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation

1 reference

12 December 2020

Hyperglycemia associated with olanzapine

1 reference

12 December 2020

Dopamine antagonists and the development of breast cancer

1 reference

12 December 2020

Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia

1 reference

12 December 2020

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

12 December 2020

Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting

1 reference

12 December 2020

Tolerability and adherence issues in antidepressant therapy

1 reference

12 December 2020

Novel antipsychotics and severe hyperlipidemia

1 reference

12 December 2020

Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

1 reference

12 December 2020

Psychoactive drugs and human sexual behavior: the role of serotonergic activity

1 reference

12 December 2020

Rates and correlates of suicide attempts in first-admission psychotic patients

1 reference

12 December 2020

Sexual side effects of antipsychotic medication: evaluation and interventions

1 reference

12 December 2020

Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents

1 reference

12 December 2020

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

12 December 2020

Antipsychotic-induced weight gain: a review of the literature

1 reference

12 December 2020

Determining the optimal dose of haloperidol in first-episode psychosis

1 reference

12 December 2020

Adverse effects of antipsychotic drugs

1 reference

12 December 2020

Prolonged erections associated with ziprasidone treatment: a case report.

1 reference

12 December 2020

Postpsychotic depression in schizophrenia

1 reference

12 December 2020

Twice-yearly exams unnecessary for patients taking quetiapine

1 reference

12 December 2020

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

1 reference

12 December 2020

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

1 reference

12 December 2020

Fatal cardiac event following initiation of risperidone therapy

1 reference

12 December 2020

Neuroleptic-induced deficit syndrome: old problem, new challenge

1 reference

12 December 2020

Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol

1 reference

12 December 2020

Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi.

1 reference

12 December 2020

A study of quetiapine: efficacy and tolerability in psychotic adolescents

1 reference

12 December 2020

Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

12 December 2020

Various risks of osteoporosis in patients with pituitary adenomas

1 reference

12 December 2020

Effects of development on olanzapine-associated adverse events

1 reference

12 December 2020

Schizophrenia--a high-risk factor for suicide: clues to risk reduction

1 reference

12 December 2020

Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study

1 reference

12 December 2020

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol

1 reference

12 December 2020

Priapism associated with two atypical antipsychotic agents

1 reference

12 December 2020

Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

1 reference

12 December 2020

Atypical antipsychotic drugs and hyperglycemia in adolescents

1 reference

12 December 2020

Diabetes as a result of atypical anti-psychotic drugs--a report of three cases

1 reference

12 December 2020

Suicide among schizophrenics: a review

1 reference

12 December 2020

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

1 reference

12 December 2020

Mortality and causes of death in first admitted schizophrenic patients

1 reference

12 December 2020

1 reference

12 December 2020

Drug-induced torsade de pointes. Incidence, management and prevention

1 reference

12 December 2020

The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England

1 reference

12 December 2020

Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials

1 reference

12 December 2020

Cost of relapse in schizophrenia

1 reference

12 December 2020

Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome

1 reference

12 December 2020

Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone

1 reference

12 December 2020

Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.

1 reference

12 December 2020

The Epidemiology of Psychosis: The Suffolk County Mental Health Project

1 reference

12 December 2020

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

1 reference

12 December 2020

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

12 December 2020

A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year

1 reference

12 December 2020

Risperidone side effects.

1 reference

12 December 2020

First-episode schizophrenia: the importance of early intervention and subjective tolerability.

1 reference

12 December 2020

Movement disorders associated with neuroleptic treatment.

1 reference

12 December 2020

Rationale and guidelines for the inpatient treatment of acute psychosis

1 reference

12 December 2020

The risk of medication-free research

1 reference

12 December 2020

Common treatment goals of antipsychotics: acute treatment

1 reference

12 December 2020

Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders

1 reference

12 December 2020

Risperidone-induced prolactin elevations in premenopausal women with schizophrenia.

1 reference

12 December 2020

Research in schizophrenia and the discontinuation of antipsychotic medications

1 reference

12 December 2020

Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial

1 reference

12 December 2020

How often do patients with psychosis fail to adhere to treatment programmes? A systematic review

1 reference

12 December 2020

Priapism associated with conventional and atypical antipsychotic medications: a review

1 reference

12 December 2020

Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.

1 reference

12 December 2020

Depression in first-episode schizophrenia

1 reference

12 December 2020

Circumstances of suicide among individuals with schizophrenia

1 reference

12 December 2020

Hyperglycemia and olanzapine

1 reference

12 December 2020

Adverse events related to olanzapine

1 reference

12 December 2020

Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.

1 reference

12 December 2020

10.2165/00003495-200565080-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1050343149

0 references

1 reference